Rapid, Automated, At-Line Adenovirus Quantitation Using Octet^® BLI 

Overview

Viral vector vaccines offer the advantage of a rapid response to emerging pathogens or even personalized cancer treatments. Adenoviruses (AV) represent one of the most versatile and well characterized viral vectors that have been used for clinical applications up to today. Besides their proven record of safety, one of their key advantages is the ability to trigger potent and long-lasting immunity that comprise humoral (antibody) as well as cellular immune (T-Cell) responses.

However, analytical methods for the development and manufacturing of adenoviral biopharmaceuticals are still challenging and require continuous improvement to facilitate fast and reliable vector quantification and functional assessment. Traditional methods are time and labor intensive and not practical for rapid at-line. measurement of viral titer during development and in manufacturing. 

In this application note, we report the development of a rapid, high-throughput capsid assay for AV quantification on the Octet^® BLI platform that demonstrates excellent precision and reliability.

Authors: Thomas Kruse¹, Timo Königsmann¹, Alexander D Douglas², Carina Joe², Ivan Krylov³, Yuanyuan Zhang³, David Apiyo³, Julia Niemann¹ and Markus Kampmann¹

<sup><sub>1. Sartorius Corporate Research, August-Spindler-Straße 11, 37079 Göttingen, DE
2. Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
3. Sartorius Corporation, 47661 Fremont Blvd, Fremont, CA 94538 USA</sub></sup>

Access the App Note